Cost-effectiveness assessment of alternative surveillance measures for bovine tuberculosis using stochastic modeling simulation

被引:0
|
作者
Hanitravelo, Giffona Loysell Justinia [1 ,2 ,3 ,4 ]
Lhermie, Guillaume [2 ,3 ,4 ,5 ,6 ]
Manriquez, Diego [7 ]
Henaux, Viviane [8 ]
Durand, Benoit [9 ]
Raboisson, Didier [2 ,3 ,4 ]
机构
[1] Ecole Super Agr, Res Unit LARESS, 55 Rue Rabelais, F-49007 Angers, France
[2] UMR ASTRE, CIRAD, Montpellier, France
[3] Univ Montpellier, ASTRE, CIRAD, INRAE, Montpellier, France
[4] Univ Toulouse, ENVT, F-31300 Toulouse, France
[5] Univ Calgary, Fac Vet Med, Calgary, AB T2N 1N4, Canada
[6] Univ Calgary, Sch Publ Policy, Calgary, AB T2N 1N4, Canada
[7] Colorado State Univ, Dept Anim Sci, AgNext, Ft Collins, CO 80526 USA
[8] Univ Lyon, Unite Epidemiol & Appui Surveillance, ANSES, Lab Lyon, 31 Ave Tony Garnier, F-69007 Lyon, France
[9] Univ Paris Est, Unite Epidemiol, ANSES, Lab Sante Anim, 14 Rue Pierre & Marie Curie, F-94700 Maisons Alfort, France
关键词
Bovine tuberculosis; Surveillance; Policy; Cattle; Multiscale model; NETWORK ANALYSIS; CATTLE; SPREAD;
D O I
10.1016/j.prevetmed.2025.106443
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
To respond to the increasing bovine Tuberculosis (bTB) infection rates observed in France since 2010, national authorities are considering alternative surveillance measures for bTB in Reinforced Screening Areas, defined as municipalities within 5 or 10 km range of a bTB outbreak. The objective of this study was to determine the costeffectiveness, from the farmer expenses point of view, of three alternatives to the current mandatory surveillance scenario applied on French dairy, beef and small (<10 heads) farms located in Reinforced Screening Areas (RSA), using stochastic economic and epidemiologic modeling simulation. These alternative measures include reducing bTB minimum screening age for the annual screening program (M1), systematic bTB screening before animal movement (M2), and performing an interferon-gamma test (INF-gamma) instead of strict quarantine and post-mortem diagnosis after a bTB positive test (M3). We show that the implementation of M1 and M2 increases annual costs ranging from <euro>6 to <euro>828 per farm and from <euro>56 to <euro>647 per farm, respectively, whereas the implementation of M3 led to average annual cost reductions between <euro>3 and <euro>352 per farm. These reductions were linked to fewer animals culled for post-mortem diagnostic and to a lower probability of farm quarantine or exclusion from the international markets. We also show that using a combination of the three alternatives measures in RSA farms could lead to detect between 11 and 17 additional bTB outbreaks per year. A highly cost-effective set of measures is to keep M1 at 24 months old while implementing M2 and M3. This strategy has an average annual cost of <euro>209 per farm and allows to detect 11 additional bTB outbreaks per year compared with the baseline program. The most cost-effectiveness policy to detect more bTB outbreaks, minimizing the marginal cost of additional bTB outbreak detection, is to establish M1 at 14 months while implementing M2 and M3. This approach had average annual cost of <euro>352 per farm and allowed to detect 15 additional bTB outbreaks per year. As a conclusion, the assessment of alternative surveillance measures through simulation stochastic models could assist policymakers to implement surveillance policy that balances disease monitoring costs and health outcomes. The present work supports the adoption of M1, M2 and M3 and reducing the minimum screening age at annual testing to 14 months.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
    Portnoy, Allison
    Clark, Rebecca A.
    Quaife, Matthew K.
    Weerasuriya, Chathika K.
    Mukandavire, Christinah
    Bakker, Roel
    Deol, Arminder K.
    Malhotra, Shelly
    Gebreselassie, Nebiat
    Zignol, Matteo
    Sim, So Yoon
    Hutubessy, Raymond C. W. G.
    Baena, Ines Garcia A.
    Nishikiori, Nobuyuki
    Jit, Mark
    White, Richard G.
    Menzies, Nicolas A.
    PLOS MEDICINE, 2023, 20 (01)
  • [42] Modeling the Cost-Effectiveness of the Integrated Disease Surveillance and Response (IDSR) System: Meningitis in Burkina Faso
    Somda, Zana C.
    Perry, Helen N.
    Messonnier, Nancy R.
    Djingarey, Mamadou H.
    Ki, Salimata Ouedraogo
    Meltzer, Martin I.
    PLOS ONE, 2010, 5 (09):
  • [43] COST-EFFECTIVENESS OF ULTRASOUND VS MRI FOR HEPATOCELLULAR CARCINOMA SURVEILLANCE IN CIRRHOSIS: A COMPARATIVE MODELING STUDY
    Anya, Eugenia Uche
    Wilechansky, Robert M.
    Balogun, Oluwafemi
    Simon, Tracey
    Chhatwal, Jagpreet
    Corey, Kathleen E.
    GASTROENTEROLOGY, 2023, 164 (06) : S1409 - S1410
  • [44] Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile
    Yeatman, Timothy J.
    Schell, Michael J.
    Sause, William
    JAMA NETWORK OPEN, 2020, 3 (03)
  • [45] COST-EFFECTIVENESS ANALYSIS OF COUNTERMEASURES USING ACCIDENT CONSEQUENCE ASSESSMENT MODELS
    ALONSO, A
    GALLEGO, E
    RADIATION PROTECTION DOSIMETRY, 1987, 21 (1-3) : 151 - 158
  • [46] Economic appraisal of energy efficiency in buildings using cost-effectiveness assessment
    Tuominen, Pekka
    Reda, Francesco
    Dawoud, Waled
    Elboshy, Bahaa
    Elshafei, Ghada
    Negm, Abdelazim
    8TH NORDIC CONFERENCE ON CONSTRUCTION ECONOMICS AND ORGANIZATION, 2015, 21 : 422 - 430
  • [47] Commentary: Moving Toward Cost-Effectiveness in Using Psychophysiological Measures in Clinical Assessment: Validity, Decision Making, and Adding Value
    Youngstrom, Eric A.
    De Los Reyes, Andres
    JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY, 2015, 44 (02): : 352 - 361
  • [48] Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales
    Rafia, Rachid
    Brennan, Alan
    Madan, Jason
    Collins, Karen
    Reed, Malcolm W. R.
    Lawrence, Gill
    Robinson, Thompson
    Greenberg, David
    Wyld, Lynda
    VALUE IN HEALTH, 2016, 19 (04) : 404 - 412
  • [49] A SIMULATION MODELING OF THE EFFECT OF DOSING SCHEDULE ON THE BENEFIT AND COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN CANADA
    Ismaila, A. S.
    Pereira, J. A.
    Robson, R. C.
    Rawson, N. S.
    Simpson, S. D.
    Standaert, B. A.
    VALUE IN HEALTH, 2009, 12 (03) : A163 - A163
  • [50] Cost-Effectiveness of Neonatal Hearing Screening Programs: A Micro-Simulation Modeling Analysis
    Verkleij, Mirjam L.
    Heijnsdijk, Eveline A. M.
    Busse, Andrea M. L.
    Carr, Gwen
    Goedegebure, Andre
    Mackey, Allison R.
    Qirjazi, Birkena
    Uhlen, Inger M.
    Sloot, Frea
    Hoeve, Hans L. J.
    de Koning, Harry J.
    EAR AND HEARING, 2021, 42 (04): : 909 - 916